Gain Therapeutics, Inc.
GANXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Gain Therapeutics, Inc. focuses on Biotechnology services and products. Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Valued at $55.0M, GANX is a micro-cap name in its sector. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Market Cap
$55.0M
Beta
0.19
P/E (TTM)
—
P/E (Fwd)
-1.83
EPS (TTM)
$-0.50
EPS (Fwd)
$-0.69
ROE
-268.3%
ROA
-95.5%
Cash
$13.1M
Total Debt
$609,874
Free CF
-$11.1M
52W Change
-35.4%
Annual Financials
Cash vs Debt
Where GANX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GANX finished 31.32% below its 150-day moving average ($1.82) and 34.90% below its 200-day moving average ($1.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GANX overbought or oversold?
At the October 20, 2026 close, GANX's RSI(14) was 14.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $13.1M in cash comfortably exceeding the $610K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$11.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -268.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $140K (2022) to $0 (2025), a 100% decline worth watching.
GANX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Gain Therapeutics, Inc.'s trajectory.